Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 6/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.59 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.59 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.59 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.59 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.59 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6162227 | 0.91 | MEN1 (0.56) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| Besonprodil SCHEMBL2257896 | 0.85 | GRIN1 (0.66) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| Besonprodil SCHEMBL29388542 | 0.85 | GRIN1 (0.66) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL6162014 | 0.79 | GRIN1 (0.54) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL3447803 | 0.78 | GRIN2B (0.65) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL8109942 | 0.78 | GRIN1 (0.74) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL6161379 | 0.78 | GRIN1 (0.51) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL6161788 | 0.76 | GRIN1 (0.54) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4675791 | 0.76 | GRIN1 (0.71) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL6163800 | 0.76 | GRIN1 (0.62) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1089735-B1 | 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-06-08 | — | — | EP | claimed |
| US-20030004187-A1 | Method for preventing dyskinesias | WARNER-LAMBERT COMPANY LLC | 2003-01-02 | — | — | US | claimed |
| EP-1254661-A1 | Method for preventing dyskinesias with selective NMDA-Antagonists | WARNER-LAMBERT COMPANY (US) | 2002-11-06 | — | — | EP | claimed |
| US-6284774-B1 | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY | 2001-09-04 | — | — | US | claimed |
| EP-1089735-B1 | 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20030004187-A1 | Method for preventing dyskinesias | WARNER-LAMBERT COMPANY LLC | 2003-01-02 | — | — | US | disclosed |
| EP-1089735-A4 | 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1254661-A1 | Method for preventing dyskinesias with selective NMDA-Antagonists | WARNER-LAMBERT COMPANY (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6284774-B1 | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY | 2001-09-04 | — | — | US | disclosed |
| EP-1089735-A1 | 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | Warner-Lambert Company LLC (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000000197-A1 | 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004187-A1 | Method for preventing dyskinesias | GRIN2B, GRIN2A, GRIN3A | GRIN1 4/4885GRIN2B 1/4885GRIN2D 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.